Universität zu Köln

Mueller, Dirk, Fischer, Kirsten, Kaiser, Peter, Eichhorst, Barbara, Walshe, Ronald, Reiser, Marcel, Kellermann, Lenka, Borsi, Lisa, Civello, Daniele, Mensch, Alexander, Bahlo, Jasmin, Hallek, Michael, Stock, Stephanie and Fingerle-Rowson, Guenter (2016). Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leuk. Lymphoma, 57 (5). S. 1130 - 1140. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

The cost-effectiveness of rituximab in combination with fludarabine/cyclophosphamide (R-FC) for the first line treatment of chronic lymphocytic leukemia (CLL) was evaluated. Based on long-term clinical data (follow-up of 5.9 years) from the CLL8-trial, a Markov-model with three health states (Free from disease progression, Progressive disease, Death) was used to evaluate the cost per quality-adjusted life-year (QALY) and cost per life years gained (LYG) of R-FC from the perspective of the German statutory health insurance (SHI). The addition of rituximab to FC chemotherapy results in a gain of 1.1 quality-adjusted life-years. The incremental cost-effectiveness ratio (ICER) of R-FC compared with FC was Euro17 979 per QALY (Euro15 773 per LYG). Results were robust in deterministic and probabilistic sensitivity analyses. From the German SHI perspective, rituximab in combination with FC chemotherapy represents good value for first-line treatment of patients with CLL and compares favorably with chemotherapy alone.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Mueller, Dirk UNSPECIFIED UNSPECIFIED UNSPECIFIED Fischer, Kirsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Kaiser, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichhorst, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Walshe, Ronald UNSPECIFIED UNSPECIFIED UNSPECIFIED Reiser, Marcel UNSPECIFIED UNSPECIFIED UNSPECIFIED Kellermann, Lenka UNSPECIFIED UNSPECIFIED UNSPECIFIED Borsi, Lisa UNSPECIFIED UNSPECIFIED UNSPECIFIED Civello, Daniele UNSPECIFIED UNSPECIFIED UNSPECIFIED Mensch, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Bahlo, Jasmin UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Stock, Stephanie UNSPECIFIED UNSPECIFIED UNSPECIFIED Fingerle-Rowson, Guenter UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-290232
DOI:	10.3109/10428194.2015.1070151
Journal or Publication Title:	Leuk. Lymphoma
Volume:	57
Number:	5
Page Range:	S. 1130 - 1140
Date:	2016
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1029-2403
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language THERAPY; LIFE; DIAGNOSIS; LYMPHOMA; QLQ-C30; GERMANY Multiple languages Oncology; Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/29023